ResearcherShenzhen UniversityActive in the last 2 years

Tianbao Wang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5144276386. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2026: 1 paper

Papers 1

Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glycolysis in pancreatic cancer. Last author DOI 10.1038/s41419-026-08958-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shiyu Chen · 1 shared paper, 2026 · strength 0.29
- Paper Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glyc… DOI 10.1038/s41419-026-08958-w ↗
Kun Cai · 1 shared paper, 2026 · strength 0.29
- Paper Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glyc… DOI 10.1038/s41419-026-08958-w ↗
Zhiwei He · 1 shared paper, 2026 · strength 0.29
- Paper Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glyc… DOI 10.1038/s41419-026-08958-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.